The US Food and Drug Administration (Fda) authorizes the awaited Alzheimer's drug from Eisai and Biogen.
In studies performed
, Leqembi has shown promising results for the treatment of the disease
, which affects about 6.5 million Americans, with an evident slowdown of the disease.
The FDA has given the drug
an accelerated
green light , which means that the two companies will have to conduct more studies.
The drug will cost $26,500 a year per person
, US media reported.
"Alzheimer's is a very disabling disease for those affected and has devastating effects for the people who are close" to the patients.
"This treatment option is the latest to target the underlying process of Alzheimer's, rather than treating the symptoms of the disease," says FDA's Billy Dunn